Lon Avct News Today

Avacta Group Plc (LON:AVCT – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 87 ($1.10) and last traded at GBX 87.98 ($1.11), with a volume of 2122802 shares traded. The stock had previously closed at GBX 91.50 ($1.15). Avacta Group Stock Performance The […]

Shares of Avacta Group Plc (LON:AVCT – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as GBX 87 ($1.10) and last traded at GBX 87.98 ($1.11), with a volume of 2122802 shares. The stock had previously closed at GBX 91.50 ($1.15). Avacta Group Price Performance The stock […]

Avacta Group Plc (LON:AVCT – Get Rating)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 127.50 ($1.60) and traded as low as GBX 106 ($1.33). Avacta Group shares last traded at GBX 107.50 ($1.35), with a volume of 855,588 shares trading […]

Avacta Group Plc (LON:AVCT – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 128.03 ($1.59) and traded as low as GBX 106 ($1.32). Avacta Group shares last traded at GBX 108.50 ($1.35), with a volume of 508,969 shares. Avacta Group Stock […]

Shares of Avacta Group Plc (LON:AVCT – Get Rating) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 128.20 ($1.60) and traded as low as GBX 120.66 ($1.51). Avacta Group shares last traded at GBX 123 ($1.54), with a volume […]

Shares of Avacta Group Plc (LON:AVCT – Get Rating) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 124.79 ($1.53) and traded as low as GBX 113.50 ($1.39). Avacta Group shares last traded at GBX 114.50 ($1.41), with a volume […]

28 May 2021 | 09:46am StockMarketWire.com - Cancer therapies and diagnostics Avacta said it had yet to receive any update from the UK Medicines and Healthcare products Regulatory Agency on the CE mark submission for its SARS-CoV-2 antigen lateral flow test. Its partner, Mologic Limited had filed the CE application. To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so, the company said. At 9:46am: [LON:AVCT]...

6 April 2021 | 09:26am StockMarketWire.com - Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the companysSARS-CoV-2 research Affimer reagents. Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avactas SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue. At 9:26am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p Story provided by ...

Avacta signs diagnostic licensing deal with Biokit

Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021